Opus Genetics (IRD) rated Hold: valuation hinges on AAV gene therapy success. Track LCA5 Phase 3, 2026 data catalysts & ...

Adeno‑associated virus (AAV) vectors offer safety and durable expression but lack tumor specificity. This hypothesis proposes ...

AAVone ® 2.1 has achieved ~1x10 16 genome copies (GC)/L of cell culture and greater than 70% full capsids at harvest, representing a significant advance over AAVone ® 1.0 and conventional ...

Call may be accessed by dialing (833) 659-8620 (U.S.) or (409) 767-9247 (international) and using conference ID# 8879216 Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic ...

- Simultaneous delivery of two optimized AAV vectors expands the therapeutic and commercial potential of AGTC's industry-leading AAV platform by enabling delivery of DNA encoding larger proteins - ...

With gene therapy rapidly shifting from orphan to prevalent indications, the demand for viral vectors is surging—especially for adeno-associated virus (AAV). Yet the industry is still primarily ...

CRISPR–Cas9 delivery by adeno-associated virus (AAV) holds promise for gene therapy but faces critical barriers on account of its potential immunogenicity and limited payload capacity. Here, we ...

Maximizing the efficiency of the adeno-associated virus (AAV) platform for gene therapy is the aim of a new pilot project of the National Institutes of Health (NIH). The NIH Platform Vector Gene ...

ROCKVILLE, Md., May 8, 2026 /PRNewswire/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® single-plasmid AAV production ...